Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA)

Cancer Science

Volumn 99, Issue 11, 2008, Pages 2224-2229

  Kountourakis, Panteleimon ^a   Psyrri, Amanda ^a   Scorilas, Andreas ^b   Camp, Robert ^c   Markakis, Sonia ^b   Kowalski, Diane ^c   Diamandis, Eleftherios P ^d   Dimopoulos, Meletios A ^b  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN 6; PACLITAXEL; PLATINUM COMPLEX; TUMOR MARKER;

ADULT; ADVANCED CANCER; ANALYTIC METHOD; ARTICLE; AUTOMATED QUANTITATIVE ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

AUTOMATIC DATA PROCESSING; COHORT STUDIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; KALLIKREINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 55449091482     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00942.x     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E et al. American Cancer Society. Cancer statistics, 2008. CA Cancer J Clin 2008; 54: 71-96.
2. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82: 1535-8.
3. Paliouras M, Diamandis EP. The kallikrein world: An update on the human tissue kallikreins. Biol Chem 2006; 387: 643-52.
4. Yousef GM, Chang A, Scorilas A et al. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000; 276: 125-33.
5. Paliouras M, Diamandis EP. Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Res Treat 2006; 102: 7-18.
6. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53(8):1423-32.
7. Talieri M, Diamandis EP, Gourgiotis D et al. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: A new potential biomarker for prognosis of breast carcinoma. Thromb Haemost 2004; 91(1): 180-6.
8. Diamandis EP, Yousef GM. Human Tissue Kallikreins: A family of new cancer biomarkers. Clin Chem 2002; 48: 1198-205.
9. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997; 80: 1529-37.
10. Yousef GM, Polymeris ME, Yacoub GM et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003; 63: 2223-7.
11. Psyrri A, Kountourakis P, Scorilas A. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Ann Oncol 2008; 19(7): 1271-7.
12. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment GW: Geneva, 1979; 16-21.
13. Rimm DL, Camp RL, Charette LA et al. Tissue microarray: A new technology for amplification of tissue resources. Cancer J 2001; 7: 24-31.
14. Psyrri A, Kountourakis P, Yu Z et al. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis (AQUA) elucidates prognostic patient subsets. Ann Oncol 2007; 18(4): 709-15.
15. Hoffman BR, Katsaros D, Scorilas A et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: A new independent unfavourable prognostic biomarker. Br J Cancer 2002; 87(7): 763-71.
16. Komatsu N, Saijoh K, Toyama T et al. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br J Dermatol 2005; 153(2): 274-81.
17. Diamandis EP, Yousef GM, Soosaipillai AR et al. Human kallikrein 6 (zyme/ protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem 2000; 33: 79-83.
18. Psyrri A, Kassar M, Yu Z et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005; 11: 8637-43.
19. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8(11): 1323-7.
20. Altman DG, Lausen B, Sauerbrei W et al. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86(11): 829-35.
21. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10(21): 7252-9.
22. Yu Z, Weinberger PM, Provost E et al. beta-Catenin functions mainly as an adhesion molecule in patients with squamous cell cancer of the head and neck. Clin Cancer Res 2005; 11(7): 2471-7.
23. Yousef GM, Luo LY, Scherer SW et al. Molecular characterization of zyme/ protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics 1999; 62(2): 251-9.
24. Prezas P, Arlt MJ, Viktorov P et al. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem 2006; 387: 807-11.
25. Diamandis EP, Scorilas A, Fracchioli S et al. Kallikrein 6 (KLK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003; 21(6): 1035-43.